Applicant, as named in the Orange Book

Arcutis

Arcutis Biotherapeutics Inc · Nasdaq: ARQT

Company and ticker: cliffwatch mapping, checked against SEC EDGAR · SEC filings

Next listed expiry: Zoryve on 25 Aug 2037. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Zoryve NDA 215985 · 3 strengths roflumilast	roflumilast	25 Aug 2037 patent, carve-out possible	patent, carve-out possible
Zoryve NDA 217242 roflumilast	roflumilast	19 Aug 2042 patent	patent

Zoryve · Exclusivity expires within 90 days NPExclusivity expires 15 Dec 2026Detected 24 Oct 2026